Time-Restricted Eating Eases IBS-C Symptoms in Study

Time-Restricted Eating Shows Promise for Easing IBS-C Symptoms

In a single-group pilot study from Kristiania University College, 134 patients with Irritable Bowel Syndrome (IBS) followed a time-restricted eating (TRE) protocol for eight weeks. Participants, including those with the constipation-predominant subtype (IBS-C), ate within an 8-hour daily window and fasted for 16 hours. The group saw a significant average drop in symptom severity scores.

IBS-C Patients Saw a 125-Point Drop in Symptom Scores with Fasting Windows

The pilot study, led by Clausen and Sverdrup, used the validated IBS Symptom Severity Scale (IBS-SSS) to measure changes. A total score reduction of 50 points is considered clinically meaningful. The 97 participants who completed the intervention achieved a mean reduction of 100.2 points. For the IBS-C subgroup specifically, the improvement was even more pronounced, with a mean reduction of 125.2 points.

This structured eating pattern does more than just limit caloric intake. It provides the digestive tract with a prolonged, uninterrupted rest period. During this fasting window, a critical self-cleaning mechanism called the migrating motor complex (MMC) can operate effectively. The MMC acts as a “housekeeper wave,” sweeping residual food particles and bacteria from the small intestine down into the colon. When eating occurs too frequently, this cycle is disrupted, potentially contributing to bloating, bacterial overgrowth, and slowed motility—common issues in IBS-C. By consolidating meals, TRE may strengthen the MMC’s activity, promoting more regular bowel movements. The study also reported secondary benefits in participants’ self-reported physical and mental health.

It is important to note this was a single-group, pre-post pilot study without a control group. While the results are encouraging, they require confirmation through randomized controlled trials. Furthermore, the lead author disclosed a conflict of interest related to book royalties on the topic.

Rifaximin May Offer a Targeted Approach for Overlapping SIBO and IBS-C

Symptom overlap between IBS-C and small intestinal bacterial overgrowth (SIBO) is common, creating a complex clinical picture. A 2026 systematic review by Shah and Soldera evaluated the effectiveness of three common antibiotics: metronidazole, bismuth, and rifaximin.

The review suggests rifaximin holds particular promise. Unlike metronidazole, which is absorbed systemically and can cause side effects like nausea and neuropathy, rifaximin acts locally within the gut lumen with minimal absorption. This localized action allows it to reduce bacterial populations in the small intestine with fewer systemic side effects, making it a more targeted option. Bismuth compounds are also poorly absorbed and can act as a mild antimicrobial and intestinal protectant, though evidence for their standalone efficacy is less robust.

For an individual with IBS-C and confirmed SIBO, a course of rifaximin could help reduce gas-producing bacteria that cause bloating and pain. Clearing this overgrowth may, in turn, help normalize gut motility. The SIBO Complete Guide details testing protocols and combination therapies often needed to prevent relapse, a common challenge after antibiotic treatment.

Integrating Meal Timing and Microbial Management for Constipation Relief

The evidence points toward a dual-pathway strategy for managing IBS-C, especially when SIBO is suspected. One pathway focuses on restoring the body’s intrinsic rhythm through meal timing, while the other addresses microbial imbalances directly.

Adopting a 16:8 eating schedule is a behavioral intervention with mechanistic plausibility. Allowing a consistent 16-hour fast nightly gives the MMC adequate time to complete multiple cycles, potentially improving colonic transit. Patients could start by gradually delaying their first meal of the day or advancing their last meal, aiming for an eating window of, for example, 11 AM to 7 PM. This approach is detailed further in our article on Time-Restricted Eating for IBS-C.

When bacterial overgrowth is present, this dietary rhythm may need pharmacological support. Following a positive breath test, a clinician might prescribe a targeted antibiotic like rifaximin. The goal is to reset the small intestinal environment, after which consistent meal timing and perhaps a prokinetic agent can help maintain the results by supporting continued MMC function.

Supporting the gut microbiome during and after any intervention is also key. Incorporating specific probiotic strains with evidence for IBS, or using prebiotic fibers to feed beneficial bacteria, can help cultivate a more resilient microbial community less prone to overgrowth. This integrated model—combining structured eating, targeted antimicrobials, and microbiome support—represents a functional approach to a multifactorial problem.

Conclusion

Emerging research supports a structured, two-pronged strategy for IBS-C management. Evidence indicates time-restricted eating can significantly reduce symptom severity, likely by enhancing gut motility cycles. For cases involving SIBO, the non-absorbed antibiotic rifaximin provides a targeted treatment option. Combining these approaches addresses both the timing of digestion and the microbial environment of the gut.

Sources:
https://pubmed.ncbi.nlm.nih.gov/41829935/
https://pubmed.ncbi.nlm.nih.gov/41809172/
https://pubmed.ncbi.nlm.nih.gov/41745639/